Description: Aspira Women’s Health Inc. (formerly known as Vermillion, Inc. Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1®plus combines our FDA-cleared products OVA1® and OVERA® to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiXSM testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.
Home Page: aspirawh.com
AWH Technical Analysis
Building III
Austin,
TX
78738
United States
Phone:
512 519 0400
Officers
| Name | Title |
|---|---|
| Ms. Valerie Barber Palmieri | Exec. Chairwoman |
| Ms. Nicole Sandford CPA | Pres, CEO & Director |
| Ms. Marlene McLennan | Interim CFO and Interim Principal Financial & Accounting Officer |
| Dr. Ryan Phan M.D., Ph.D. | Chief Operating & Scientific Officer |
| Mr. Sean Rowe | Sr. VP of Technology |
| Ms. Minh Merchant | Gen. Counsel & Corp. Sec. |
| Ms. Emily Granger | Director of Marketing |
| Mr. Gregory Richard | Sr. VP of Market & Bus. Devel. |
| Dr. Charles J. Dunton M.D. | Interim Chief Medical Officer |
| Mr. Michael J. Newton | Sr. VP of Commercial |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Supplies |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.0625 |
| Price-to-Sales TTM: | 5.5529 |
| IPO Date: | 1996-06-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 106 |